+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rigel Pharmaceuticals Inc - logo

Rigel Pharmaceuticals is a clinical-stage biotechnology company that focuses on the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of a variety of diseases. It has been in trials for rheumatoid arthritis, autoimmune thrombocytopenia, lymphoma and others. In addition, Rigel also has two oncology product candidates in development. Founded in 1996, Rigel is headquartered in San Francisco, California.

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • December 2022
  • 83 Pages
  • Global
From
Autoimmune Hemolytic Anemia Therapeutics Market 2024-2028 - Product Thumbnail Image

Autoimmune Hemolytic Anemia Therapeutics Market 2024-2028

  • Report
  • June 2024
  • 145 Pages
  • Global
From
Warm Autoimmune Hemolytic Anemia (WAIHA) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Warm Autoimmune Hemolytic Anemia (WAIHA) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • March 2024
  • 134 Pages
  • Global
From
Gout Therapeutics Global Market Report 2024 - Product Thumbnail Image

Gout Therapeutics Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032 - Product Thumbnail Image

Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032

  • Report
  • September 2023
  • 79 Pages
  • Global
From
Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 133 Pages
  • Global
From
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 504 Pages
  • Global
From
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 696 Pages
  • Global
From
Psoriasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Psoriasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 875 Pages
  • Global
From
Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast - Product Thumbnail Image

Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast

  • Report
  • May 2024
  • 240 Pages
  • Global
From
Autoimmune Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Autoimmune Collaboration and Licensing Deals 2016-2024

  • Report
  • October 2024
  • 500 Pages +
  • Global
From
Immune Thrombocytopenia Drug Market (2024 Edition): Analysis By Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others), By Type, By End-User, By Region: Market Insights and Forecast (2019-2029) - Product Thumbnail Image

Immune Thrombocytopenia Drug Market (2024 Edition): Analysis By Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others), By Type, By End-User, By Region: Market Insights and Forecast (2019-2029)

  • Report
  • March 2024
  • 254 Pages
  • Global
From
Co-Promotion and Co-Marketing in Pharmaceuticals and Biotechnology 2014-2024 - Product Thumbnail Image

Co-Promotion and Co-Marketing in Pharmaceuticals and Biotechnology 2014-2024

  • Report
  • September 2024
  • 250 Pages
  • Global
From
Transforming growth factor beta inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Transforming growth factor beta inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 150 Pages
  • Global
From
Rheumatoid Arthritis (Immunology) - Drugs in Development, 2021 - Product Thumbnail Image

Rheumatoid Arthritis (Immunology) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Global Anaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026 - Product Thumbnail Image

Global Anaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026

  • Report
  • April 2021
  • 190 Pages
  • Global
From
Novel Drug Reconstitution Systems Market by Type of Container, Fabrication Material, Physical State of Drug in Syringe and Cartridge, Physical State of Drug in Infusion Bag, Volume of Container, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030 - Product Thumbnail Image

Novel Drug Reconstitution Systems Market by Type of Container, Fabrication Material, Physical State of Drug in Syringe and Cartridge, Physical State of Drug in Infusion Bag, Volume of Container, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • Report
  • September 2021
  • 325 Pages
  • Global
From
Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hidradenitis Suppurativa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 106 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • April 2022
  • 160 Pages
  • Global
From
Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024 - Product Thumbnail Image

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Loading Indicator